Member Info for sadoldgit

In addition it should make its way into journals.

Good morning Celtic007,

The peer review will be pretty much in line with the data supplied.

Review will be supplied as an external unbiased account of data provided.

It will carry more clout of course than a manufacturers claim.

So it is important that this review is undertaken.

Preferably by those with no conflict of interests.

Will give far greater in depth detail too.

Regards

Regards

AI Overview

+2

Janus kinase (JAK) inhibitors are a potential treatment for systemic lupus erythematosus (SLE). JAK inhibitors are small-molecule drugs that can: Regulate intracellular signal transduction, Suppress pro-inflammatory cytokines, Inhibit inflammatory immune cells, and Lead to SLE disease remission without corticosteroids.

JAK inhibitors are effective in treating musculoskeletal and mucocutaneous involvement in SLE, but they have poor effects on lupus nephritis and serological activity. The efficacy of JAK inhibitors on cutaneous lupus erythematosus is uncertain.

Some JAK inhibitors that have shown merit as treatments for SLE include:

Tofacitinib

A JAK1/3 inhibitor that reduced cholesterol levels, improved vascular function, and decreased the type I interferon signature in SLE patients

Baricitinib

A JAK1/2 inhibitor that demonstrated significant improvements in lupus rashes and arthritis

Some safety concerns associated with the use of JAK inhibitors in patients with SLE include infections and thromboembolism.

Point of interest here is efficacy being shown but slight concerns on safety.

Baricitinib has boxed warnings. Yet it is being trialled in SLE and ultimately long term treatment.

Baricitinib Jak1 and Jak2.

The problem here which most of us know is the Jak2 problems associated with h0m0 dimerisation

It does not happen with Tyk2

In fact Tyk2 himerdimerises with jak2.

I find it strange that certain people here cannot grasp the understandings of toxicology studies.

BARICITINIB IS APPROVED FOR CLINICAL USE!

BARICITINIB HAS BOXED WARNINGS.

There is by the very nature that we are not Jak2 selective highly unlikely to experience adverse events leading to boxed warnings.

No increase in creatinine levels albeit comparatively short dosage time.

Much toxicology work was carried out in preclinical.

There has been no observation of any myocardial concerns with 1801.

Now one thing we did not do was establish a maximum tolerated dose, this is not to be confused with a maximum therapeutic dose.

We tested at over 30 times maximum therapeutic dose in preclinical with no occurrence of dose

limiting events.

There are people on here who claims to see both sides and the ups and the downs the negatives and positives.

A question l would ask them is-

How much value will be achieved on the release of toxicology study with a favourable safety profile of which was released in a recent RNS indicative that on the data they so far have points to a favourable safety profile.

Better than Beprocitinib with regards to safety?

Clearly Tim looked into this. Some here want to constantly find fault with him.

One thing he did say is that what Sareum are very good at is chemistry.

He is a very modest person.

I am inclined to go along with what Tim believes in with regards to our compounds.

Tell me what that like to pull any positivity apart is what is the worst case scenario and the

'Baricitinib is a drug that is being studied as a potential treatment for Alzheimer's disease, but it is not currently approved for this use:

Clinical trials

A trial is currently underway at Massachusetts General Hospital and Holy Cross Hospital in Florida to test baricitinib in people with Alzheimer's disease or at risk for it. The trial is expected to finish in mid-2024. '

Should prove interesting. We have similar profile but with the added bonus of TYK2 and not JAk2, we would benefit immensely.

Regards to all

I think you need to get yourself a bit more clued up Enki

Potential Efficacy: The drug has shown potential in treating autoimmune diseases, particularly plaque psoriasis, with significant tumor regression in preclinical models2.

Try reading what drivel you have copied and pasted before posting.

1801 is auto immune

1802 is immuno oncology.

It has googled the thread l started yesterday Rebster408.

It just goes to prove how little it knows.

Tim and Co are pushing for 1801 to be best in class. Clearly they believe in it.

I would tend to follow in their field of expertise their opinions as opposed to a highly self opinionated little fool that does not know the difference between immunotherapy and immuno oncology. It might just be a case of it needed some more sleep. More than likely out of its depth.

Clearly some snippets of information it has just recently googled is too much for it to fully comprehend.

My opinion FWIIW

All goes well 1801 should be comparable with Deucravacitinib as to a value at end of phase2.

Attention to detail l have found normally pays off.

Of course we also have 1802 back in development now.

As for competitors, yes it is a very competitive area immunotherapy, Tim pointed that out in 2021, They also stated they believed that in some Indications 1801 would out perform Deucravacitinib and in some cases vica versa.

Enki.

What was so special with upfront payment of 4 billion dollars for Deucravacitinib?

Is it safer or more efficacious than 1801?

If you believe it is more safer please explain your reasonings for this.

Are there actual advantages of allosteric TYK2 which interact via the JH2 as opposed to JH1 domain?

BMS claims it regulates.

If this is the case why is its performance mediocre in Psoriasis and failed to reach its endpoints in Psoriasis?

Many inhibitors trying to push into the SLE market.

Baricitinib is one with a boxed warning safety profile.

Ok in Phase 2 but failed in phase3

Is SLE a probable indication for 1801?

What about sepsis?

What about the cytokine storm?

Baricitinib approved for emergency use for cytokine storm.

Surely 1801 is vastly superior to Baricitinib.

Have a good day

Good morning BECKS007.

May l suggest you take a look at

Triparna Sen you tube 2019 first

Then Triparna Sen l think around June 2024 it last s for just under 50 mins.

First is good

2nd is very good and l would say better than the first.

There is plenty of info around on this one.

Regards

Carter19

Sra737 was very well tolerated with low dose gemcitabine.

By combining gemcitabine with 737 it proved effective as a treatment whilst at the same time reducing toxicity due to around 50% reduction in the gemcitabine dose.

Potnak what you on about' SOG you know why the extended tox study can result in a failure.'

No, l don't.

Perhaps you could enlighten me by supplying the detailed information that relates to long term unexpected toxicology problems with early TYK2 inhibitors.

Which are these inhibitors

Are these inhibitors TYK2 only or contain other Jaks?

There are failures with some Tyk2 inhibitors but that as far as l know is down to efficacy and not toxic off target effects of TYK2

Perhaps you could list these Inhibitors and the adverse toxic event that led to their demise.

Allosteric Tyk2 inhibitors do not have boxed warnings unlike the other Jak inhibitors irrespective of selectivity.

As we inhibit jak1 as well as Tyk2 we will be labelled boxed warnings unless proven otherwise.

As l have said jak inhibitors are given black box warnings by the NIH irrespective of selectivity.

Baricitinib has boxed warning it has not stopped it being approved for clinical use in RA.

Apart from a poor attempt to strike fear into potential investors l see no point in your misleading post.

Are you sure you are invested here?

If you are take your own intimated risk of failure advice and sell up. You would be doing us all.a favour.

By the way send an email to BMS and remind them of the 4 billion they paid for Deucravacitinib at the end of phase 2 clinical trial that they too could find long term toxicology effects that could cause failure.

Deucravacitinib with one of the best safety profiles of a kinase inhibitor does have adverse effects. I am sure you are well aware of this.

I really don't know where to start to point you in the right direction to understand these compounds,

As for Riverfort l believe Sareum and most likely Tim led up the garden path by sharks.

I take it your saw the little heart on the RF linked I n website informing all of this brilliant deal for the customer.

The heart was posted by Tim on same day Aug 3rd.

Effectively what they are saying here is the extrachromasomal DNA is not inhibited by CHK2 inhibition.

Extrachromasomal DNA has a marked affect on oncogenes as l understand. Basically through very prolific mutation creating cancerous cells.

Also bare in mind that CCT245737 in combination with LDG gave good toxicity profile.

'Conclusions: SRA737 in combination with low-dose gemcitabine was well tolerated with lower myelotoxicity than has been seen at standard doses of gemcitabine or with other combinations of Chk1 inhibitors with gemcitabine. Tumor responses were observed in anogenital and other solid tumors.'

Regards

Potnak,

Please, please, please come back here and explain what exactly with regards to toxicology would be regarded as a deal breaker?

Do you know or don't you?

When the MHRA stated there were unable to approve phase1 clinical trial you painted nothing but doom and gloom about 1801.

Ie there must be something wrong with it that the BoD have not told us about?

Potnak do you honestly believe that the multiple deluge of posts from the likes of Puma and MAJWANDCO had no effect on share price?

Potnak you put:-

'I've been forced to lie to customers knowing that there is a resolution but it means admiting a failing or mismanagement.'

My work has never put me in that situation but l know others that have mistated what l have said in order to provide management with something they want to hear.

A fact can be resolved but lies grow like a cancer and indeed become acceptable as form of behaviour to the liar. To such an extent that so many people lie nowadays from politicians to used car salesman.

Clearly a society has been created that has all but removed integrity completely. You only have to look at world events over the past few years.

Look at the biggest propoganda item in households.

The TV it sits in a room constantly on feeding the brain with what those that control the politicians want you to hear.

The only way people can make head way now is undermine others and not achieve what they want by their own intended efforts.

Great post Elcap by the way.

Regards

Https://pubmed.ncbi.nlm.nih.gov/34852220/

It won't read what l have put Bobbler, way out of its depth.

It has lost the debate.

Most can read and understand what l have put then you get the 24 carat pure unadulterated drivel that the imbecile believes is a smart reply.

A child could put up a better argument.

Potnak could do better, that saying something

Ìt really is absolutely clueless.

Regards.

As there are a large number of FDA approved kinase inhibitors for various indications, their repurposing for viral infections is an attractive and time-sparing strategy. Many kinase inhibitors, including baricitinib, ruxolitinib, imatinib, tofacitinib, pacritinib, zanubrutinib, and ibrutinib, are under clinical investigation for COVID-19. Herein, we discuss FDA approved kinase inhibitors, along with a repertoire of clinical/preclinical stage kinase inhibitors that possess antiviral activity or are useful in the management of viral infections.

Copyright © 2021 American Chemical Society

Below from a naysayer, am sure even Potnak could have made a better attempt at trying to undermine kinase inhibitors.⁷

'Tyrosine kinase 2 (TYK2) and Janus kinase (JAK) inhibitors are not commonly used because of the potential side effects and risks associated with them.'

No mention of course of the numerous compounds already approved.

No mention ofthe upfront payment of 4 billion dollars paid for a Tyk2 kinase inhibitor.

Come on wolfies mate, you must try much harder, you really are out of your depth sonny.

Regards

Delays to research work caused by Covid19.

https://pmc.ncbi.nlm.nih.gov/articles/PMC10275655/

There is no typical length of time it takes for a drug to be tested and approved. It might take 10 to 15 years or more to complete all 3 phases of clinical trials before the licensing stage. But this time span varies a lot. There are many factors that affect how long it takes for a drug to be licensed.1 Feb 2022

https://www.cancerresearchuk

As you will note a slightly different portrayal from the post below.

When we are looking at averages

Are we looking at the mode the mean or the median.

Which should be the applicable average here?

That WIP claimed inside information

Claimed he new what was going on with new production facilities

Claimed that everything with SRA737 was all hush hush and heavily password protected.

A con man l feel.

Sucked quite a few in.

Gsk were looking to increase treatment in oncology.

Gsk had recently paid 5.1 billion for Tesaro pipeline.

In combo therapy 737 and niraparib.

Gsk not want it but at the same time did not want anyone else to have it.

We do have a few doom and gloom.merchants on here.

Something wrong with 737 as handed back

Something wrong with 1801 as unable to approve phase1 clinical trial application.

Note people were posting the phrase refusal.

This is not the case as there is a slight but distinct difference.

I find the majority of exaggerated problems mentioned here are not by long term investors but short term traders. The so called in and out brigade that any share dies not perform the way they like refer to as a dog.

I spent much of my early life on some largish engineering projects.

You all need pull in the same direction.

Nothing worse than a doom monger.

By all means point out any doubts or foreseeable problems. These can be addressed.

Success is achieved by finding solutions to problems not concentrating and exaggerating any problem that exists.

If l had any doubts about the favourability of our safety and efficacy profile for our SDC Compounds, l would not be here now.

Our Tyk 2 Jak1 compounds are 100% designed and developed by Sareum.

Regards

'Doing the tox study first means a binary outcome. It means success or failure and if the study didn't go the way the board hope it will. It's the end of sareum as we know it"

No it dies not mean success or failure.

It merely indicates the favourability of the safety profile.

There may be no ill effects minor effects medium adverse effects but extremely highly unlikely to get any MACE.

What the longer term toxicology testing is doing is attempting to identify any events.

These events will be reflected in the value of the SDC compound..

Look at it as a formality!

Tim.and Co very confident clearly they know a lot more than you do Potnak.

Also take into account off target effects that have been picked up since around 2019.

Poorly reported and I deed false data supplied in attempts to get get compooi ds approved.

I have posted before on this matter!

Steps would also be undertaken to ensure data is accurate and may involve requirements for further testing.

Now many of these tests now a requirement by the likes of the NIH or similar bodies.

Once these additional toxicology investigations are completed this information will rewuire to be supplied to support its application.

Any interested party would want this data prior to any application for phase 2 trials.

So don't pass it off as success or failure.

Feel free to come back Potnak and please feel free to consult with your new buddy Enkri.

Regards

You sound like a big kid Potnak,

You not interested in the removed posts,

You admittedly have no idea whether my posts are true or not.

Since most of my posts derive from research by esteemed scientists why would they not be true?

There are some that say l post or put links that l don't understand, ye t at the same time not one single negative poster has chosen to debate on this.

You know nothing of the science as you admit.

Now l were taught that if l do not know of a subject to listen to those that do.

I could go to a Chinese restaurant order my food and drinks in mandarin and you would be none the wiser.

From what data or knowledge you have do you state your belief that company will be worth 800 million in a couple of years?

That around 6 pounds 50 per share at current share volume.

I stated a couple of years back we are potentially best in class derived from the results in preclinical trials.

Attention to detail is paying off as the formation of the capsule as a means of oral intake.

I also gave the reasons, but clearly you don't read my posts as you have already admitted, or just skip over them.

Tim is now placing 1801 as best in class with regards to Tyk2 Jak1.

Are you going to tell me Potnak that l am wrong or Tim is right? Are we both wrong or both correct.

The people that you have been attracted to have sought to destroy this company.

The likes of MAJWANDCO and Puma.

Joined 3rd Aug 23.

Doom.and gloom, price will collapse. Inside information, sell up now and make your money later, we are shorting and will come back k and make whoosh loads of money.

They not interested in you or the investor here.

Look at the comments made here at the time with discussions of the golf course games and the master coaching the youngster.

Look up the initials and they correspond to senior employees of Riverfort.

Go on linked in and find nigh the exact commentary between two employees on there

You Potnak were saying we should have listened to them.

What would have been the result had we done that?

No more Sareum, their primary intent was to force sareum onto administration.

Rf senior employee also looking into selling on companies in financial difficulty one in administration.

Something that RF create.

You claim to look at things from both sides.

I see things from both sides but focus on the negatives as see the end goal as licence or takeover.

I am not surprised people ask you to leave meetings with your attitude , certainly would not want to go on and adventure with you, first T junction you come to would not know whether to turn left or right, put sunglasses on or open up your umbrella

Please hurry back when you have another opinion you would like to discuss as l would be .ore than happy to debate here.

As for the point of not caring less, then why bring me in to your arrogant one sided opinion.

Regards

1x 10k at 26p

Then 3 at 27p

Sell 1 at 25p

1 at 24p

Price is being kept low. 140k above mid price a few thousand below and we sit static.

The link

https://www.cell.com/iscience/fulltext/S2589-0042(24)01200-8

Note that much of this data that the information will have originated from will be SO.

Interesting to note also is the limited availability of SRA737 compound dut to materials limitations agreements by SO.

Michelle Garrett had covered considerable in combo studies with 737 up until around mid 2020 when after this period in combo chk1 studies were carried out with prexasertib.

Prexasertib is now onlicenced to Acrivon as we know.

Is it just coincidence that from around May 2020 the ' for sale' sign came down on 737, all development was ceased, some if the funding was taken to support Momoletonib, Stephen Dilley came on board and lastly but not leastly limitations of availability for the 737 compound.

July 2024 is the recent date of 737 studies in a journal, question is :- who is behind entering this report into the journal?

Chk1 will have an advantage in some strains of ovarian cancer. Crucial to this is biomarker data ( albeit Acrivon have their own platform which they consider will give areas of greater success than biomarker data) is recognising or to be more precise, establish areas where CHK1 in combo therapy likely to prove most effective.

Whilst not by the very nature of this basically individually tailored patient treatment, being of high commercialisation value, it nonetheless will prove invaluable in areas of high urgent unmet need. That is my conclusive opinion.

As yet the full potential of CHK1 is unrealised with inroads being taken with respect to Alzheimers Disease and this in combo with FLT3.

Regards.